It was reported here in March 2017 that BioTime, Inc. is conducting a Phase I/IIa clinical trial for OpRegen® for treatment of dry AMD. OpRegen is a retinal pigment epithelium (RPE) stem cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA). RPE cells are essential [Read More]
News
The Dangers of Night Driving Glasses
Reprinted courtesy of Laramy-K Optical Lab It is an all too common misconception that yellow tinted or yellow polarized night driving glasses are beneficial for night time driving. The thought is, the yellow or amber color reduces glare and improves contrast. However, in reality, when driving at night or dusk in already limited lighting conditions, [Read More]
Correcting Misconceptions About AMD
(Updated 7/29/19) Age-related macular degeneration (AMD) is a progressive disease of the retina wherein the light-sensing cells in the central area of vision (the macula) stop working and eventually die. The disease is thought to be caused by a combination of genetic and environmental factors, and it is most common in people who are age [Read More]
Travels With Charlie
About the Author Travel Companions Why Travel? Mobility Let’s Go For a Walk Vision and Seeing Let Your Ears Be Your Eyes A Computer and You The Final Journey, Part 1 The Final Journey, Part 2 Friends, Neighbors, and Relations: Alternative Sources for Transportation About the Author Charlie Zell was president of the Organization of Macular [Read More]
Charles Bonnet Syndrome Officially Recognized
After years of intensive public education efforts about the causes and symptoms of a mysterious hallucinatory condition affecting visually impaired people, Prevent Blindness and other patient advocacy organizations are pleased that Charles Bonnet Syndrome will soon be officially recognized by eye care professionals around the world. As described in the latest revision of the International [Read More]